Revacept: Collagen GP VI receptor inhibitor, a new & a formidable target for antiplatelet action

Sangeeta Bhanwra, Kaza Ahluwalia, Kavita Sekhri

Abstract


Antiplatelet drugs play an important role in the prevention as well as treatment of cardiovascular diseases like coronary artery disease and stroke. Many of the currently available antiplatelet drugs face limitations due to safety and efficacy issues. A new antiplatelet drug, revacept i.e. a collagen receptor antagonist, has been shown to reduce platelet adhesion by blocking GP VI-dependent pathways without increasing the risk of bleeding complications and without affecting the general hemostasis.


Keywords


Platelet adhesion, Revacept, Collagen GP VI receptor inhibitor

Full Text:

PDF

References


Ungerer M, Rosport K, B├╝ltmann A, Piechatzek R, Uhland K, Schlieper P, et al. Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 2011;123:1891-9.

Deckmyn H, De Meyer SF, Bross K, Vanhoorelbeke K. Inhibitors of the interactions between collagen and its receptors on platelets. Handb Exp Pharmacol 2012;(210):311-37.

Nieswandt B, Watson SP. Platelet-collagen interaction: is GPVI the central receptor? Blood 2003;102:449-61.

Xiang YZ, Xia Y, Gao XM, Shang HC, Kang LY, Zhang BL. Platelet activation, and antiplatelet targets and agents: current and novel strategies. Drugs 2008;68:1647-64.

Gruner S, Prostredna M, Koch M, Miura Y, Schulte V, Jung SM, et al. Relative antithrombotic effect of soluble GPVI dimer compared with anti-GPVI antibodies in mice. Blood 2005;105:1492-9.

Gruner S, Prostredna M, Aktas B, Moers A, Schulte V, Krieg T, et al. Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy. Circulation 2004;110:2946-51.

Schulte V, Reusch HP, Pozgajova M, Varga-Szabo D, Gachet C, Nieswandt B. Two-phase antithrombotic protection after anti-glycoprotein VI treatment in mice. Arterioscler Thromb Vasc Biol 2006;26:1640-7.

Poppert H. Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02). Available at http://clinicaltrials.gov/show/NCT01645306. NLM Identifier: NCT01645306. Accessed 8 February 2013.

Bultmann A, Li Z, Wagner S, Peluso M, Schonberger T, Weis C, et al. Impact of glycoprotein VI and platelet adhesion on atherosclerosis: a possible role of fibronectin. J Mol Cell Cardiol 2010;49:532-42.